Clearside Biomedical, Inc. (CLSD)

Clearside Biomedical, Inc. filed for Chapter 11 bankruptcy protection, causing a significant stock price decrease. Prior to this, the stock had already experienced a substantial decline over the past year. Other notable events include a Q2 2025 earnings miss, Q1 2025 financial results, exploration of strategic alternatives, XIPERE approval in Canada, presentations at medical congresses, and FDA alignment on CLS-AX Phase 3.

Information regarding demand seasonality specifically for Clearside Biomedical, Inc.'s products and services was not found in the provided search results.

Clearside Biomedical, Inc. is a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal space (SCS®). Their SCS Microinjector® platform enables targeted delivery of therapies to treat sight-threatening eye diseases. Key products include XIPERE™ (approved for macular edema associated with uveitis) and CLS-AX (in development for wet AMD). They are also evaluating small molecules for geographic atrophy (GA) and diabetic macular edema (DME).

Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia, United States, with employees across North America and Europe. XIPERE is approved in the U.S., Canada, Australia, and Singapore. Arctic Vision holds an exclusive license for commercialization and development in Greater China, South Korea, Australia, New Zealand, India, and ASEAN Countries.

Clearside Biomedical's brand reputation has been negatively impacted by its recent financial distress and bankruptcy filing. Before the bankruptcy announcement, positive developments included FDA alignment for CLS-AX, product approvals and partnerships, and participation in ophthalmology events. However, the bankruptcy filing overshadows these positive developments.

Clearside Biomedical, Inc.'s ownership is a mix of institutional, insider, and public/individual investors. Institutional investors own approximately 68.64% to 72.22% of the company's stock, insiders own 21.54%, and public companies and individual investors own 3.58% to 6.24%. Major institutional owners include Vanguard Group Inc, Geode Capital Management, Llc, and BlackRock, Inc.